The CALINA study tested a new ratio and dose of Coartem to account for metabolic differences in babies under 5 kg
2024 full-year revenue guidance raised by US$ 2 billion
Keimed is a leading wholesale pharma distribution with industry leading operating metrics
New solvent-free micronization technology expanded at the Darmstadt site in Germany
NULIBRY is a first-in-class synthetic cPMP substrate replacement therapy to reduce the risk of mortality in patients with MoCD Type A
Around 7% of the Indian population suffers from IBS
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
NM5072 is an anti-Properdin antibody that selectively blocks the alternative pathway while maintaining the integrity of the classical pathway required for fending off infections
Global Phase-3 study initiation expected in the second half of 2024
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
Subscribe To Our Newsletter & Stay Updated
